deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT02993406

Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo (CLEAR Outcomes)

A Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Bempedoic Acid (ETC-1002) on the Occurrence of Major Cardiovascular Events in Patients With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant

Sponsor: Esperion Therapeutics, Inc.

Conditions Cardiovascular Diseases Statin Adverse Reaction
Interventions Bempedoic acid 180 mg tablet Matching placebo tablet
Updated 28 times since 2017 Last updated: Dec 13, 2023 Started: Dec 22, 2016 Primary completion: Nov 7, 2022 Completion: Nov 7, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Cardiovascular Diseases and Statin Adverse Reaction and is currently completed. Esperion Therapeutics, Inc. leads this study, which shows 28 recorded versions since 2016 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~May 2018 · 3 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Aug 2019 · 3 months · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Sep 2022 · 11 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Feb 2024 · 13 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 8 months · monthly snapshot

Change History

28 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  5. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE3

▶ Show 23 earlier versions

  1. Jan 2023 — Feb 2024 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Sep 2022 — Jan 2023 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  4. Feb 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE3

  6. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

  7. Jun 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE3

  8. Mar 2020 — Jun 2020 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE3

  10. May 2019 — Aug 2019 [monthly]

    Recruiting PHASE3

  11. Apr 2019 — May 2019 [monthly]

    Recruiting PHASE3

  12. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE3

  13. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE3

  14. Dec 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  15. Nov 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  16. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  17. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE3

  18. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE3

  19. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  20. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  21. Feb 2018 — May 2018 [monthly]

    Recruiting PHASE3

  22. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

  23. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

Dec 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Esperion Therapeutics, Inc.
  • The Cleveland Clinic
Data source: Esperion Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Aalborg, Denmark , Aalst, Belgium , Abington, United States , Adamstown, Australia , Adana, Turkey (Türkiye) , Adelaide, Australia , Aguascalientes, Mexico , Ahmedabad, India , Airdrie, United Kingdom and 822 more locations